Hematologic Oncology

The phase 2 SANRECO trial met its primary end point, with 88% of this polycythemia vera population achieving a response with divesiran vs 19% with placebo.

Updated results from the phase 2 ELIANA trial support tisa-cel as definitive therapy for pediatric and young adult patients with relapsed/refractory B-ALL.

Pirtobrutinib plus venetoclax/rituximab reduced the risk of progression or death by 45% among those with CLL in the phase 3 BRUIN CLL-322 trial.

Transplant-associated thrombotic microangiopathy GVHD are related, but distinct consequences of endothelial injury after allogeneic HCT.

Clinicians “still don’t have the answer” on true toxicity thresholds, says Tiba Al Sagheer, PharmD, BCOP, BCACP, on CAR T-cell toxicity management.

The world of cellular therapy is “still ever-expanding” as novel constructs continue to emerge, according to Megan Melody, MD.

The approval of Orca-T validates many years of work dedicated to manipulating the graft to improve outcomes among patients undergoing allogeneic transplant.

Whether Orca-T competes with post-transplant cyclophosphamide for GVHD prevention must be studied prospectively, said Wendy Stock, MD.

The FDA approval of Orca-T represents an “important advance” in the world of allogeneic transplant, according to Wendy Stock, MD.

Data from the phase 3 Precision-T trial support the FDA approval of allogeneic regulatory T-cell–based immunotherapy.

Julie M. Vose, MD, MBA, discussed how the digital age is impacting oncology care.

This year’s EHA Congress saw potential advances across multiple myeloma, leukemia, lymphoma, and other hematologic malignancy populations.

Updated phase 1/1b BGB-11417-101 trial data showed sonrotoclax 320 mg plus zanubrutinib achieved uMRD4 rates exceeding 90% in treatment-naive CLL/SLL.

The phase 3 EPCORE DLBCL-1 data showed epcoritamab reduced progression or death risk by 26% vs chemoimmunotherapy in relapsed/refractory LBCL.

Teclistamab monotherapy significantly improved PFS and OS vs investigator's choice in the phase 3 MajesTEC-9 trial in RRMM.

Results from the phase 3 SUCCESSOR-2 trial showed MeziKd reduced the risk of progression or death by 52% vs Kd in anti–CD38- and LEN-exposed RRMM.

Explore key insights on operationalizing bispecific antibodies in community oncology, outpatient step-up dosing, and shared staffing infrastructure.

Data from the phase 1/2 CADENZA trial support the approval of pivekimab sunirine for patients with blastic plasmacytoid dendritic cell neoplasms.

The extended-release tablet formulation may help improve patient adherence to treatment, possibly representing a more convenient, patient-friendly dosing schedule, according to Naveen Pemmaraju, MD.

Investigators evaluated how tisagenlecleucel and cilta-cel altered adverse effect timelines for patients treated for hematologic malignancies.

Naomi Cazeau, MSN, ANP-BC, AOCNP, discussed how anemia and inflammation drive psychoneurological symptoms in patients with hematologic malignancies.

Ralph V. Boccia, MD, FACP, discussed the operational hurdles of administering bispecific antibodies in community settings.

Novel bispecifics may bridge gaps in care, especially among patients in rural settings, according to Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA.

Reducing vein-to-vein time and expanding manufacturing capacity represent ongoing challenges to optimizing the use of cellular therapy across indications.

Researchers have reported that CD7 may be a viable CAR T-cell target in a subset of relapsed/refractory acute myeloid leukemia, and that fratricide-resistant CD7 CAR T cells can induce deep remissions with an encouraging early safety profile.